Candriam Luxembourg S.C.A. Increases Stock Position in Myokardia Inc (NASDAQ:MYOK)

Candriam Luxembourg S.C.A. lifted its holdings in Myokardia Inc (NASDAQ:MYOK) by 15.6% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 70,500 shares of the biotechnology company’s stock after purchasing an additional 9,500 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Myokardia were worth $5,138,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. California State Teachers Retirement System lifted its position in shares of Myokardia by 1.2% in the 3rd quarter. California State Teachers Retirement System now owns 69,233 shares of the biotechnology company’s stock worth $3,611,000 after purchasing an additional 827 shares during the period. Man Group plc acquired a new stake in Myokardia during the third quarter worth about $1,335,000. Assenagon Asset Management S.A. acquired a new stake in Myokardia during the fourth quarter worth about $3,223,000. State of New Jersey Common Pension Fund D acquired a new stake in Myokardia during the third quarter worth about $2,357,000. Finally, Castleark Management LLC acquired a new stake in Myokardia during the third quarter worth about $6,945,000.

In other Myokardia news, insider Jake Bauer sold 21,232 shares of Myokardia stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $65.17, for a total transaction of $1,383,689.44. Following the completion of the sale, the insider now directly owns 53,134 shares in the company, valued at $3,462,742.78. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Anastasios Gianakakos sold 5,000 shares of Myokardia stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $65.02, for a total transaction of $325,100.00. Following the sale, the chief executive officer now owns 90,864 shares of the company’s stock, valued at $5,907,977.28. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 89,828 shares of company stock valued at $6,099,362. Company insiders own 4.30% of the company’s stock.

Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. restated a “buy” rating on shares of Myokardia in a research report on Friday, February 7th. Credit Suisse Group raised their price objective on shares of Myokardia from $77.00 to $82.00 and gave the stock a “positive” rating in a research report on Tuesday. BidaskClub cut shares of Myokardia from a “buy” rating to a “hold” rating in a research report on Saturday, January 18th. ValuEngine cut shares of Myokardia from a “buy” rating to a “hold” rating in a research report on Friday, January 3rd. Finally, Maxim Group restated an “average” rating on shares of Myokardia in a research report on Monday, October 28th. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $82.36.

Shares of MYOK opened at $70.40 on Friday. Myokardia Inc has a 1-year low of $41.66 and a 1-year high of $78.28. The stock has a market cap of $3.25 billion, a PE ratio of -13.49 and a beta of 2.09. The firm has a 50-day simple moving average of $71.42 and a two-hundred day simple moving average of $61.19.

Myokardia Profile

MyoKardia, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM.

Featured Story: Bond

Want to see what other hedge funds are holding MYOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myokardia Inc (NASDAQ:MYOK).

Institutional Ownership by Quarter for Myokardia (NASDAQ:MYOK)

Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.